FREMONT, Calif., March 4 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, today highlighted recent accomplishments across its diagnostic test programs and provided a preview of key business milestones it plans to achieve over the course of 2008. The Company also released financial results for the fourth quarter and year ended December 31, 2007.
"In 2007, Vermillion made significant clinical and commercial advancements in our diagnostic programs for peripheral artery disease (PAD), ovarian cancer and thrombotic thrombocytopenic purpura (TTP)," said Gail Page, President and CEO of Vermillion. "Our vision is to provide novel diagnostic tools to physicians in an effort to improve patient diagnosis and care. We continue to build awareness of the potential value proposition of our tests. Our primary focus will be on commercialization pathways in 2008."
Throughout the fourth quarter of 2007 and into the first quarter of
2008, Vermillion has advanced its PAD and ovarian cancer diagnostic
programs, as well as accomplished numerous achievements at the corporate
PAD Diagnostic Test Progress
-- Completed a 540-patient clinical study evaluating the ability of
Vermillion's multi-marker panel to stratify individuals into high and
low risk groups for PAD. These results have been accepted for
publication in a peer-reviewed clinical journal and are expected to be
published in the first half of this year.
-- Entered into an exclusive license agreement with Stanford University to
develop and commercialize a biomarker panel used to assess the risk of
PAD. Under the terms of the agreeme
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved